January 14, 2022

New real-world data show high rate of patient adherence to Tepezza for thyroid eye disease (TED) – Horizon Therapeutics

Horizon Therapeutics plc announced findings of a real-world adherence analysis of Tepezza for the treatment of TED ( Thyroid Eye Disease) at the American Academy of Ophthalmology Annual Meeting (AAO 2021). Tepezza is the first and only medicine approved by the FDA for the treatment of TED – a serious, progressive and potentially vision-threatening rare autoimmune disease. The analysis found […]

admin Health 0 38 sec read
November 1, 2021

Phase III MIRROR trial of Krystexxa meets primary endpoint in chronic gout – Horizon Therapeutics

Horizon Therapeutics announced topline results of the phase III MIRROR trial met the primary endpoint, showing a significant increase in efficacy using Krystexxa (pegloticase injection) with the immunomodulator methotrexate as compared to the response rate of Krystexxa with placebo for people with chronic gout refractory to conventional therapies – also known as uncontrolled gout. Results were from the Methotrexate to […]

admin Health 0 51 sec read
May 11, 2021

New analysis of Uplizna for neuromyelitis optica spectrum disorder is published in Neurology Neuroimmunology & Neuroinflammation – Horizon Therapeutics

Copyright © ICR (UK) Limited t/a International Medical Information (IMI). Registered in the UK Company no. 05894351 medicalupdateonline.com is brought to you by International Medical Information. For more details, visit http://www.medicalimi.com Disclaimer: All information on this site has been collated by healthcare professionals from around the globe. Where every possible step has been taken to ensure its accuracy, MedicalUpdateOnline cannot […]

admin Health 0 27 sec read

Archives

Categories

Meta

Recent Posts

Recent Comments